Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Effect of adjuvant chemotherapy in locally advanced urothelial carcinoma of the ...
Journal Information
Vol. 44. Issue 2.
Pages 94-102 (March 2020)
Download PDF
More article options
Vol. 44. Issue 2.
Pages 94-102 (March 2020)
Original article
Effect of adjuvant chemotherapy in locally advanced urothelial carcinoma of the bladder treated with cystectomy
Efecto de la quimioterapia adyuvante en el carcinoma urotelial de vejiga localmente avanzado tratado con cistectomía
G. del Pozo Jiméneza,
Corresponding author

Corresponding author.
, F. Herranz Amob, J.A. Arranz Arijab, E. Rodríguez Fernándezb, D. Subirá Ríosb, E. Lledó Garcíab, G. Bueno Chomónb, M.J. Cancho Gilb, J. Carballido Rodrígueza, C. Hernández Fernándezb
a Servicio de Urología, Hospital Universitario Puerta de Hierro, Madrid, Spain
b Servicio de Urología, Hospital Universitario Gregorio Mara˜nón, Madrid, Spain
Article information
Full Text
Download PDF
Figures (2)
Tables (5)
Table 1. Clinical variables of the series and both cohorts.
Table 2. Surgical and pathological variables of the series and of both cohorts.
Table 3. Patients' condition at the end of the study.
Table 4. Multivariate analysis of CSM.
Table 5. Summary of the main clinical trials on AdjCh in the treatment for MIBT after RC.
Show moreShow less

Currently, the role of adjuvant chemotherapy (ADJ) in muscle invasive bladder tumor (MIBC) remains controversial.


To evaluate the effect of ADJ on cancer specific survival (CSS) of MIBC after radical cystectomy (RC).

Material and methods

Retrospective analysis of 292 patients diagnosed with urothelial bladder tumor (BT) pT3-4pN0/+ cM0 stage, treated with RC between 1986-2009. Total cohort was divided in two groups: 185 (63.4%) patients treated with ADJ and 107 (36.6%) without ADJ. Median follow-up was 40.5 months (IQR 55–80.5).

Comparative analysis was performed with Chi-square test and Student’s t test/ANOVA. Survival analysis was carried out with the Kaplan–Meier method and log-rank test. Multivariate analysis (Cox regression) was made to identify independent predictors of cancer-specific mortality (CSM).


42.8% of the series presented lymph node involvement after RC. At the end of follow-up, 22.9% were BC-free and 54.8% had died due to this cause. The median CSS was 30 months. No significant differences were observed in CSS regarding the treatment with ADJ in pT3pN0 (p = .25) or pT4pN0 (p = .29) patients, but it was significant in pT3-4pN+ (p = .001).

Multivariate analysis showed pathological stage (p = .0001) and treatment with ADJ (p = .007) as independent prognostic factors for CSM. ADJ reduced the risk of CSM (HR:0.59,95%CI 0.40–0.87, p = .007).


pT and pN stages were identified as independent predictors of CSM after RC. The administration of ADJ in our series behaved as a protective factor reducing the risk of CSM, although only pN + patients were benefited in the stage analysis.

Bladder tumor
Cystectomy Prognostic factors
Adjuvant chemotherapy
Cancer specific mortality

El papel de la quimioterapia adyuvante (QTAdy) en el tumor vesical músculo invasivo (TVMI) sigue siendo controvertido actualmente.


Evaluar el efecto de la QTAdy en la supervivencia cáncer específica (SCE) del TVMI tras cistectomía radical (CR).

Material y métodos

Análisis retrospectivo de 292 pacientes diagnosticados de tumor vesical (TV) urotelial tratados con CR entre 1986-2009 con estadio pT3-4pN0/+cM0, divididas en dos cohortes:185(63.4%) pacientes tratados con QTAdy y otra con 107(36.6%) sin QTAdy. Mediana de seguimiento de 40,5 meses (IQR 55-80,5).

Análisis comparativo con test Chi Cuadrado y t Student/ANOVA. Cálculo de supervivencia con el método de Kaplan-Meier y test de long-rank. Análisis multivariante (regresión de Cox) para identificar variables predictoras independientes de mortalidad cáncer específica (MCE).


El 42.8% de la serie presentó afectación ganglionar tras CR. Al finalizar el seguimiento, 22.9% estaban libres de TV y 54.8% habían fallecido por esa causa. La mediana de SCE fue de 30 meses. No se observaron diferencias significativas en SCE en función del tratamiento con QTAdy en pacientes pT3pN0p = 0,25 ni pT4pN0p = 0,29, pero sí en pT3-4pN+p = 0,001.

En el análisis multivariante se identificaron el estadio patológicop = 0,0001 y el tratamiento con QTAdyp = 0,007 como factores pronósticos independientes de MCE. La QTAdy redujo el riesgo de MCEHR:0.59,IC95%0,40-0,87, p = 0,007.


El estadio pT y pN se identificaron como variables predictoras independientes de MCE tras CR. La administración de QTAdy en nuestra serie se comportó como factor protector reduciendo el riesgo de MCE, aunque en el análisis por estadios, únicamente los pacientes pN + se vieron beneficiados.

Palabras clave:
Tumor vesical
Factores pronósticos
Quimioterapia adyuvante
Mortalidad cáncer específica


These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe to

Actas Urológicas Españolas (English Edition)

Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos